Program in Laboratory Research in Pediatric Oncology-Hematology: To continue to make progress in Pediatric Oncology-Hematology (POH), we need to perpetuate the pool of talented and trained POH physician-scientists and PhD scientists who will make POH-relevant discoveries and provide investigative leadership. Nevertheless, in the field of POH, there continues to be a shortage of young investigators with extensive laboratory research expertise. In the current funding period (2008-2013), this grant has already supported superb laboratory research training for an outstanding group of 23 physician-scientists and 5 PhD scientists who have demonstrated a high degree of productivity and commitment to careers in cancer research. In addition, these trainees have strengthened the laboratory research base in POH in the Johns Hopkins Medical Institutions (JHMI). This application again seeks support for 10 interdisciplinary postdoctoral research fellowship positions per year to fund the research training that is the major ingredient of the combined Johns Hopkins University/National Cancer Institute (NCI) Subspecialty Fellowship Training Program in POH (Joint Fellowship Training Program). Two groups of postdoctoral fellows will be supported by the grant proposed herein. The major group of trainees will be composed of physician-scientists, since the laboratory research training of academic POH physician-scientists is the primary objective of this training program. These highly selected physician-scientists will have completed the clinical year of their fellowships in the Joint Fellowship Training Program. The second (smaller) group of trainees will be composed of PhD postdoctoral scientists working at JHMI on projects highly relevant to the biology of childhood cancer and blood diseases. These strongly qualified postdoctoral trainees will be provided intensive 3-year research experiences that will prepare them for careers in cancer research. Trainees will work on projects relevant to the biology of childhood cancer and blood diseases, in the laboratories of leading scientists in the field. The trainees and their mentors will participate in an interactive, dynamic research environment bridging the JHMI and the National Institutes of Health (NIH), with an emphasis on translational research.
This program provides postdoctoral education, training, and experience in field-leading research on childhood cancer and blood diseases, principally for physician- scientist trainees during their subspecialty fellowships in pediatric oncology-hematology.
|Cooper, Stacy; Rubens, Jeffrey; Bodurtha, Joann (2017) Five Pediatric Cancers - Update on Genetic Implications. Curr Pediatr Rev 13:42-48|
|Nguyen, Bao; Williams, Allen B; Young, David J et al. (2017) FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. Oncotarget 8:10931-10944|
|Wu, M; Hamaker, M; Li, L et al. (2017) DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells. Leukemia 31:688-696|
|Guo, Hong; Cooper, Stacy; Friedman, Alan D (2016) In Vivo Deletion of the Cebpa +37 kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis. PLoS One 11:e0150809|
|Klein, Orly R; Chen, Allen R; Gamper, Christopher et al. (2016) Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. Biol Blood Marrow Transplant 22:895-901|
|Nagaria, Pratik K; Robert, Carine; Park, Tea Soon et al. (2016) High-Fidelity Reprogrammed Human IPSCs Have a High Efficacy of DNA Repair and Resemble hESCs in Their MYC Transcriptional Signature. Stem Cells Int 2016:3826249|
|Fox, Jennifer M; Moynihan, James R; Mott, Bryan T et al. (2016) Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget 7:7268-79|
|Zimmerlin, Ludovic; Park, Tea Soon; Huo, Jeffrey S et al. (2016) Tankyrase inhibition promotes a stable human naïve pluripotent state with improved functionality. Development 143:4368-4380|
|Feinberg, Andrew P; Koldobskiy, Michael A; Göndör, Anita (2016) Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet 17:284-99|
|Barakat, David J; Mendonca, Janet; Barberi, Theresa et al. (2016) C/EBP? regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion. Cancer Lett 375:152-161|
Showing the most recent 10 out of 67 publications